New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 6, 2013
11:42 EDTAMAGAMAG sees FY13 revenue $73M- $77M, consensus $79.12M
AMAG sees Feraheme U.S. net product revenues of between $63M-$67M, driven by a combination of price and double-digit volume growth; Royalties and product sales related to ex-U.S. sales of Feraheme/Rienso and recognition of milestones of approximately $10M.
News For AMAG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 26, 2015
10:00 EDTAMAGOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:20 EDTAMAGAMAG Pharmaceuticals transferred with a Market Perform at FBR Capital
FBR Capital transferred coverage of AMAG Pharmaceuticals with a Market Perform rating, a downgrade from its previous rating of Outperform. FBR believes Feraheme growth will be limited to market share gains and that Makena expectations are fully realized at current valuation levels. The firm has a $42 price target for AMAG shares.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use